Aldeyra Therapeutics is a biotechnology company ... modulators ADX-629, ADX-248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal ...

Aldeyra Therapeutics ... modulators ADX-629, ADX-248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic ...

Aldeyra Therapeutics is a biotechnology company devoted to ... Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, ADX-246, and chemically ...

Aldeyra Therapeutics ... modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases.

Aldeyra Therapeutics' dogged persistence with its drug eye disease therapy reproxalap – despite mixed results in a phase 3 trial – may be paying off. The Massachusetts-based biotech said a ...

Biotech Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for topical ocular reproxalap, a first-in-class ...

Abu Dhabi – eToro, the trading and investing platform, has added stocks listed on the Abu Dhabi Securities Exchange (ADX) to its platform. The launch follows an agreement signed last year between ADX ...

2025 Acura ADX will start at $44,980 in Canada The all-new premium crossover will come in three different trims The SUV is set to arrive at dealerships this spring Acura‘s all-new ADX crossover ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...